Taiwan-based Adimmune is preparing to start mass production of its H7N9 bird flu vaccine. The company is targeting a June start date for production and expects to manufacture 3 million doses a month when at full capacity. At this stage it is unclear if the Taiwanese government would buy the vaccine. Adimmune is continuing development nonetheless, to be ready to produce the vaccine if required. A Phase II trial of the vaccine is due to begin next month. News